Select a medication above to begin.
Rivoceranib
rivoceranib
Adult Dosing .
Dosage forms: TAB: 250 mg
Investigational New Drug (IND)
- [FDA approval denied, May 2024]
hepatocellular CA, unresectable
- [FDA approval denied]
- Info: inhibits vascular endothelial growth factor receptor 2, resulting in decr. angiogenesis, tumor growth, and cancer progression
Peds Dosing .
- Dosage forms: --
Investigational New Drug (IND)
- [FDA approval denied, May 2024]
- Info: not anticipated to be applicable to Peds population